Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Extraintestinal manifestations (EIMs) are common in patients with ulcerative colitis (UC) and can have a significant impact on patient morbidity and quality of life. We assessed the effect of adalimumab (ADA) therapy on the resolution of EIMs among patients with moderate to severe UC in clinical pra...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Travis, S, Feagan, B, Peyrin-Biroulet, L, Panaccione, R, Danese, S, Lazar, A, Robinson, A, Thakkar, R, Pappalardo, B, Petersson, J, Bereswill, M, Chen, N, Skup, M
Formato:	Journal article
Publicado em:	Oxford University Press 2017

Registros relacionados

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
por: Travis, S, et al.
Publicado em: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
por: Travis, S, et al.
Publicado em: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results From InspirADA.
por: Travis, S, et al.
Publicado em: (2017)

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
por: Sandborn, W, et al.
Publicado em: (2016)

Does it all ADA up? Adalimumab for ulcerative colitis.
por: Travis, S
Publicado em: (2011)

Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?
por: Walsh, A, et al.
Publicado em: (2018)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
por: Napolitano M, et al.
Publicado em: (2022-06-01)

Immune Thrombocytopenic Purpura as an Extraintestinal Manifestation in a Patient with Ulcerative Colitis
por: Renata de Medeiros Dutra, et al.
Publicado em: (2022-03-01)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
por: David T. Rubin, et al.
Publicado em: (2021-05-01)

Raising the bar in ulcerative colitis management
por: Fabrizio Fanizzi, et al.
Publicado em: (2024-11-01)

Pulmonary Extraintestinal Manifestation of Crohn’s Disease Treated Successfully with Adalimumab
por: Dongyeol Shin, et al.
Publicado em: (2018-09-01)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
por: Ferdinando D’Amico, et al.
Publicado em: (2019-05-01)

A Case of Syrian Child with Cerebral Infarction as an Extraintestinal Manifestation of Ulcerative Colitis
por: Riham Salloum, et al.
Publicado em: (2019-01-01)

Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations
por: Yiyoung Kwon, et al.
Publicado em: (2022-05-01)

Meta‐analysis of the association of extraintestinal manifestations with the development of pouchitis in patients with ulcerative colitis
por: K. Hata, et al.
Publicado em: (2019-08-01)

Role of Probiotics in the Management of Patients with Ulcerative Colitis and Pouchitis
por: Francesca Bernardi, et al.
Publicado em: (2024-12-01)

Multiple extraintestinal manifestations in a patient with acute severe ulcerative colitis: a case report
por: Eun Young Park, et al.
Publicado em: (2022-12-01)

Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country
por: Jesús K. Yamamoto-Furusho, et al.
Publicado em: (2020-10-01)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Eun Soo Kim
Publicado em: (2021-03-01)

Febrile neutropenia associated with adalimumab in a patient with ulcerative colitis
por: Ma’In Atallah Mohammad Abumuhfouz, et al.
Publicado em: (2024-04-01)

Albumin change predicts failure in ulcerative colitis treated with adalimumab
por: Natsuki Ishida, et al.
Publicado em: (2024-01-01)

Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis
por: Laurel L. Wessman, BS, et al.
Publicado em: (2017-07-01)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Assasi Nazila, et al.
Publicado em: (2009-12-01)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
por: Armuzzi A, et al.
Publicado em: (2013-04-01)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
por: Freeman HJ
Publicado em: (2013-11-01)

Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
por: Zhdanava M, et al.
Publicado em: (2024-04-01)

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
por: Vuitton, L, et al.
Publicado em: (2017)

Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
Publicado em: (2016-03-01)

Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
por: Sebastian Hoffmann, et al.
Publicado em: (2018-05-01)

ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY
por: Patrícia ZACHARIAS, et al.
Publicado em: (2017-10-01)

Leukocytoclastic Vasculitis as a Rare Dermatologic Extraintestinal Manifestation of Ulcerative Colitis in an Elderly Patient with Positive PR3-ANCA
por: Jacky Ng, et al.
Publicado em: (2021-01-01)

Exploring genetic associations of Crohn’s disease and ulcerative colitis with extraintestinal cancers in European and East Asian populations
por: Chengdong Yu, et al.
Publicado em: (2024-02-01)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
por: Shinji Okabayashi, et al.
Publicado em: (2017-10-01)

Comparison of long-term outcomes of infliximab and adalimumab therapy in biologic-naive patients with ulcerative colitis
por: Muhammed B. Durak, et al.
Publicado em: (2025-01-01)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Bénédicte Caron, et al.
Publicado em: (2023-01-01)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
por: Travis, S, et al.
Publicado em: (2012)

Henoch-Schönlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature
por: Joseph J. LaConti, et al.
Publicado em: (2016-01-01)

Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
por: Saleh Azadbakht, et al.
Publicado em: (2024-07-01)

Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
por: Candace L. Beilman, et al.
Publicado em: (2016-01-01)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
por: Martin Wasserbauer, et al.
Publicado em: (2022-01-01)